肾必宁治疗慢血清病及IgA肾病分子机理实验研究

Experimental Study on Molecular Mechanisms of Shenbi-ning in Treatment of Chronic Serum Disease and IgA Nephrosis

目的:探讨肾必宁治疗多种肾病机制及“异病同治”分子机理。方法:制造慢血清病及IgA肾病鼠模型。HE染色观察肾小球系膜增殖,原位末端标记法(TUNEL)检测凋亡细胞,免疫组化检测系膜区Fas、PCNA的表达。结果:肾必宁对两种模型均可促进Fas表达,减轻病理损害,与凋亡率呈正相关,治疗组与模型组相比差异有显著性(P<0.05)。结论:肾必宁通过调控Fas系膜区的表达,诱导系膜细胞凋亡,抑制增殖而治多种肾病;“异病同治”的分子基础可能是同一药物调控了不同疾病的相同基因。

Objective: To probe mechanisms of Shenbi-ning in treatment of many kinds of nephrosis and molecular mechanisms of 'treating different diseases with the same therapeutic principle '. Methods: Chronic serum disease and IgA nephrosis model rat was established, and hyperplasia of mesangium, apoptosis and Fas and PCNA expression in the mesentefic region were investigated with HE staining. TUNEL and immuno-histochemical methods, respectively. Results: Shenbi-ning could improve Fas expression, reduce pathological lesion which was positively correlated with the apoptosis rate for the two membranous types with significant difference between treatment group and model group (P<0. 05). Conclusion: Shenbi-ning treats many kinds of diseases through controlling Fas expression in the mesenteric region, inducing apoptosis in the mesentery and inhibit its hyperplasia; and molecular basis of 'treating different diseases with the same therapeutic principle' is possibly that a same drug regulates same genes of different diseases.